v3.26.3
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Apr. 06, 2026
Jan. 01, 2026
Sep. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Apr. 01, 2025
Sep. 30, 2024
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Business combination contingent consideration liability $ 68,210     $ 68,210 $ 68,210   $ 94,339    
Changes in fair value included in net income         (28,586) $ 982      
Maximum [Member]                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Changes in fair value included in net income         26,100        
SHINE                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Payment to dispose a business regarding related party transaction     $ 1,400            
Installment Note | Series E-1 Preferred Stock                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Estimated fair value   $ 70,000              
Carrying value $ 70,000 70,000              
Debt instrument, unamortized discount   2,500              
Gain on conversion   $ 2,500              
Installment Note | SHINE                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Promissory note receivable maturity date Jun. 14, 2028                
Seller Note | SHINE                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Unsecured promissory note receivable     $ 20,000            
Percentage of annual interest rate     8.00%            
Deferred Cash Purchase Price | Cash | SHINE                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     $ 25,000            
Deferred Cash Purchase Price | Cash on Earlier of January 1, 2029 | SHINE                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     20,000            
Deferred Cash Purchase Price | Cash After January 1, 2029 | SHINE                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     5,000            
SPECT                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration $ 131,200   131,222 131,200 131,200        
SPECT | Cash                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration [1]     32,141            
SPECT | Installment Note                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     67,200            
SPECT | Seller Note                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     14,500            
SPECT | Deferred Cash Purchase Price                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     12,300            
SPECT | Net Contingent Consideration Receivable                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     5,081            
SPECT | Fair Value of Contingent Consideration                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     6,500            
SPECT | Cash and capital stock                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Disposal group consideration     $ 30,000            
Life Molecular Imaging Inc                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Asset acquisition, additional milestone payments         400,000        
Milestone payments in cash         30,000        
Evergreen Theragnostics                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Business combination contingent consideration liability               $ 25,000  
Evergreen Theragnostics | Additional Remaining Payments                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Business combination contingent consideration liability $ 727,500     $ 727,500 $ 727,500        
Radiopharm Theranostics Limited                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Shares owned (in shares) 537,958,513     537,958,513 537,958,513       149,625,180
Investment owned, fair value $ 2,300     $ 2,300 $ 2,300   $ 9,000    
Share price (in dollars per share) $ 0.004     $ 0.004 $ 0.004   $ 0.02    
Perspective Therapeutics, Inc                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Shares owned (in shares) 8,739,011     8,739,011 8,739,011   11,677,339    
Investment owned, fair value $ 24,000     $ 24,000 $ 24,000   $ 32,100    
Share price (in dollars per share) $ 2.75     $ 2.75 $ 2.75   $ 2.75    
Cash from sale of securities       $ 8,600          
Shares acquired (in shares) 2,938,328     2,938,328 2,938,328        
Realized loss       $ 2,300          
Illuminated Holdings, Inc. | Installment Note | Series E-1 Preferred Stock                  
Fair Value, Option, Quantitative Disclosures [Line Items]                  
Shares owned (in shares)   2,545,454              
Conversion and cancellation amount   $ 70,000              
Note receivable Conversion Price   $ 27.5              
[1] This amount includes a net working capital settlement of $0.7 million received on July 1, 2026.